Company: BOLT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058632
Chunk: 57

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 57
---
. As of December 31, 2024, no holder held any registration rights under the IRA and the IRA had been terminated pursuant to its terms.

Relationship with Stanford University

In May 2015, we entered into a license agreement with Stanford University. During 2023, we made payments to Stanford of $89,700 for annual license fees and patent expense reimbursement. During 2024, we made payments to Stanford of $91,800 for annual license fees and patent expense reimbursement.

Dr. Engleman, a member of our Board until May 2024, is a professor at Stanford. Dr. Engleman is a co-inventor of some of the patents that we license from Stanford. Under Stanford’s policies, as a co-inventor Dr. Engleman is entitled to receive a share of any royalties that we pay to Stanford under the agreements with respect to the covered intellectual property. No royalty payments have been made to date.

Employment Arrangements

We have entered into offer letters with certain of our executive officers. For more information regarding these offer letters, see “Executive Compensation - Employment Arrangements.”

Consulting Agreements

We have entered into consulting agreements with certain of our former executive officers. For more information regarding these consulting agreements, see “Executive Compensation - Consulting Agreements.”

Equity Grants

We have granted options to certain of our directors and executive officers. For more information regarding the options granted to our directors and named executive officers, see “Executive Compensation” and “Director Compensation”.

<div align='center'>37</div>

Indemnification

We provide indemnification for our directors and officers so that they will be free from undue concern about personal liability in connection with their service to the Company. Our amended and restated certificate of incorporation contains provisions limiting the liability of directors, and our amended and restated bylaws provides that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws also provide our Board with discretion to indemnify our employees and other agents when determined appropriate by the board.

In addition, we have entered into an indemnification agreement with each of our directors, executive officers and certain employees, which requires us to indemnify them. For more information regarding these agreements, see “Information Regarding the Board of Directors and Corporate Governance —Limitations of Liability and Indemnification Matters.”

Policies and Procedures for Related Person Transactions

Our Board has adopted a related person